Clinical Trials Logo

Clinical Trial Summary

Evaluating the Efficacy and safety of Adebrelimab in Combination with Platinum-based Doublet Chemotherapy and SHR-8068 as First-line Therapy for Patients with Advanced or Metastatic NSCLC Carrying STK11/KEAP1/KRAS Mutations


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06335355
Study type Interventional
Source Shanghai Shengdi Pharmaceutical Co., Ltd
Contact Junli Qang
Phone +0518-81220121
Email Junli.wang@hengrui.com
Status Not yet recruiting
Phase Phase 2/Phase 3
Start date March 2024
Completion date October 2030

See also
  Status Clinical Trial Phase
Completed NCT02264990 - Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers Phase 3
Completed NCT01664533 - An Observational Study of Erlotinib (Tarceva) as Second-line Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Failure of Pemetrexed in First-line Therapy N/A
Completed NCT01328951 - A Study of First-line Maintenance Erlotinib Versus Erlotinib at Disease Progression in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Platinum-Based Chemotherapy Phase 3
Completed NCT00988936 - Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug Phase 2
Completed NCT00976456 - Efficacy Study of Avastin® With Pemetrexed +/- Carboplatin to Treat Elderly Patients With Non-small Cell Lung Cancer Phase 3
Completed NCT02596958 - Safety and Efficacy Study of Avastin in Locally Advanced Metastatic or Recurrent Non-small Lung Cancer (NSLC) Participants N/A
Completed NCT00974584 - A Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer Phase 1
Completed NCT00451906 - A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer. Phase 4
Completed NCT03329911 - A Comparative Study of BAT1706 and EU Avastin® in Patients With Advanced Non Squamous Non Small Cell Lung Cancer Phase 3
Not yet recruiting NCT03671538 - Non Squamous NSCLC Patients With Anlotinib Combined With Pemetrexed and Cisplatin N/A
Completed NCT01512420 - An Observational Study of Tarceva (Erlotinib) in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer With Wild-Type Epidermal Growth Factor Receptor (EGFR) Gene (WILT) N/A
Completed NCT01185847 - A Study of RO5083945 in Combination With Chemotherapy Versus Chemotherapy Alone in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer Phase 2
Completed NCT01204697 - A Study of Erlotinib [Tarceva] as Monotherapy or Intermittent Dosing With Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer. (TALISMAN) Phase 2
Terminated NCT00760929 - A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC). Phase 2
Withdrawn NCT03319316 - Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC) Phase 2
Recruiting NCT06334757 - Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure Phase 2
Recruiting NCT06396065 - Phase III Study of AK112 for NSCLC Patients Phase 3
Completed NCT01174563 - A Study on the Correlation Between Tarceva (Erlotinib) - Induced Rash and Efficacy in EGFR Mutated Participants With Advanced Non-Small Cell Lung Cancer Receiving First-Line Therapy Phase 2
Completed NCT01763671 - Paclitaxel-bevacizumab in Advanced Lung Cancer Phase 3
Terminated NCT01990261 - A Study to Assess the Survival of Non-small Cell Lung Cancer Patients Treated With Tarceva After Failed Chemotherapy Treatment. N/A